title: Evidence for an immunoregulatory role of OX2 with its counter ligand (OX2L) in the regulation of transplant rejection, fetal loss, autoimmunity and tumor growth.
abstract: Transplantation has emerged as an effective treatment for patients with end-stage organ failure. Current regimens of non-specific immunosuppressive drug treatment, which are needed life-long to prevent graft rejection, have numerous adverse side effects and increase the risk of opportunistic infections and malignancy. A major goal is to develop immunotherapeutic protocols that achieve specific tolerance. Such protocols would decrease and eventually eliminate the reliance on non-specific drug therapy. We showed that portal vein delivery of donor antigen prolongs the survival of vascularized and non-vascularized allo- and xeno-grafts, and that increased graft survival is associated with altered cytokine production and augmented expression of the molecule OX2. This review documents further evidence for a more general immunoregulatory role for the interactions of OX2 and its ligand, OX2L.
authors.affiliation: The Toronto Hospital, University Health Network, Ontario, Canada. rgorczynski@transplantunit.org
authors.forename: R M
authors.initials: RM
authors.lastname: Gorczynski
mesh_terms: D000022:Abortion, Spontaneous / Q000276:immunology*; D000818:Animals; D015703:Antigens, CD; D000954:Antigens, Surface / Q000235:genetics / Q000378:metabolism*; D015551:Autoimmunity; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy; D016030:Kidney Transplantation / Q000276:immunology; D008024:Ligands; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology; D011247:Pregnancy; D016038:Skin Transplantation / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014158:Transcription, Genetic; D014181:Transplantation Immunology
chemical_list: D015703:Antigens, CD; D000954:Antigens, Surface; D008024:Ligands; C042739:antigens, CD200